

- High Performance Computing (HPC)

**Thomas Santucci,**

Director, Division of IT Modernization, Office of Technology Policy, Office of Government-wide Policy, General Services Administration.

[FR Doc. 2024–11436 Filed 5–23–24; 8:45 am]

BILLING CODE 6820–68–P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Agency for Toxic Substances and Disease Registry**

[Docket No. ATSDR–2024–0001]

**Availability of Three Draft Toxicological Profiles**

*Correction*

In notice document 2024–09662, appearing on pages 36820 through 36821 in the issue of Friday, May 3, 2024, make the following correction:

On page 36820, in the first column, in the **DATES** section, on the second line, “May 3, 2024” should read “August 1, 2024”.

[FR Doc. C1–2024–09662 Filed 5–23–24; 8:45 am]

BILLING CODE 0099–10–D

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

[Docket No. CDC–2024–0043]

**Meeting of the Advisory Committee on Immunization Practices**

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice and request for comment.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC) announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public. Time will be available for public comment.

**DATES:** The meeting will be held on June 26, 2024, from 8 a.m. to 5:10 p.m., EDT, June 27, 2024, from 8 a.m. to 5:15 p.m., EDT, and June 28, 2024, from 8:30 a.m. to 12 p.m., EDT (times subject to change); see the ACIP website for updates: <https://www.cdc.gov/vaccines/acip/index.html>.

Written comments must be received between June 3–17, 2024.

**ADDRESSES:** You may submit comments, identified by Docket No. CDC–2024–

0043, by either of the methods listed below. CDC does not accept comments by email.

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments.

- **Mail:** Ms. Stephanie Thomas, ACIP Meeting, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24–8, Atlanta, Georgia 30329–4027. Attn: Docket No. CDC–2024–0043.

**Instructions:** All submissions received must include the Agency name and docket number. All relevant comments received in conformance with the <https://www.regulations.gov> suitability policy will be posted without change to <https://www.regulations.gov>, including any personal information provided. For access to the docket to read background documents or comments received, go to <https://www.regulations.gov>.

The meeting will be webcast live via the World Wide Web. The webcast link can be found on the ACIP website at <https://www.cdc.gov/vaccines/acip/index.html>.

**FOR FURTHER INFORMATION CONTACT:**

Stephanie Thomas, Committee Management Specialist, Advisory Committee on Immunization Practices, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24–8, Atlanta, Georgia 30329–4027. Telephone: (404) 639–8836; Email: [ACIP@cdc.gov](mailto:ACIP@cdc.gov).

**SUPPLEMENTARY INFORMATION:**

**Purpose:** The Advisory Committee on Immunization Practices (ACIP) is charged with advising the Director, Centers for Disease Control and Prevention (CDC), on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, the Committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines. Further, under applicable provisions of the Affordable Care Act and Section 2713 of the Public Health Service Act, immunization recommendations of ACIP that have been approved by the Director, CDC, and appear on CDC immunization schedules generally must be covered by applicable health plans.

**Matters to be Considered:** The agenda will include discussions on influenza vaccines, chikungunya vaccine, COVID–19 vaccines, pneumococcal vaccines, meningococcal vaccines, Human

papillomavirus (HPV) vaccines, Respiratory Syncytial Virus (RSV) vaccines for adults, RSV vaccines for maternal and pediatric populations, a combined diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus influenzae type B conjugate, and hepatitis B vaccine (Vaxelis®), and dengue vaccine. Recommendation votes are scheduled for influenza vaccines, COVID–19 vaccines, pneumococcal vaccine, Vaxelis®, and RSV vaccines for adults. A Vaccines for Children (VFC) vote is scheduled for Vaxelis®. Agenda items are subject to change as priorities dictate. For more information on the meeting agenda, visit <https://www.cdc.gov/vaccines/acip/meetings/index.html>.

**Meeting Information:** The meeting will be webcast live via the World Wide Web. For more information on ACIP, please visit the ACIP website: <https://www.cdc.gov/vaccines/acip/index.html>.

**Public Participation**

Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on <https://www.regulations.gov>. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/near-duplicate examples of a mass-mail campaign. CDC will carefully consider all comments submitted into the docket.

**Written Public Comment:** The docket will be opened to receive written comments on June 3–17, 2024. Written comments must be received by June 17, 2024.

**Oral Public Comment:** This meeting will include time for members of the public to make an oral comment. Oral public comment will occur before any scheduled votes, including all votes relevant to the ACIP’s Affordable Care Act and Vaccines for Children Program roles. Priority will be given to individuals who submit a request to make an oral public comment before the